Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
View Patent ↗The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human cancer. A variety of chromosomal regions (MCRs) and markers corresponding thereto, are provided, wherein alterations in the copy number of one or more of the MCRs and/or alterations in the amount, structure, and/or activity of one or more of the markers is correlated with the presence of cancer.
1. A method of assessing whether a subject is afflicted with multiple myeloma, the method comprising:
a) determining the amount of a marker in a subject sample comprising plasma cells, wherein the marker is PRKCi;
b) determining a normal amount of the marker in a non-multiple myeloma control sample comprising plasma cells; and
c) comparing the amount of the marker in the subject sample and the normal amount of the marker in the non-multiple myeloma control sample,
wherein a significant increase in the amount of the marker in the subject sample relative to the normal amount of the marker in the non-multiple myeloma control sample is an indication that the subject is afflicted with multiple myeloma.
2. A method of assessing whether a subject is afflicted with multiple myeloma, the method comprising:
a) determining the amount of a marker in a subject sample comprising plasma cells, wherein the marker is SEMA4A;
b) determining a normal amount of the marker in a non-multiple myeloma control sample comprising plasma cells; and
c) comparing the amount of the marker in the subject sample and the normal amount of the marker in the non-multiple myeloma control sample,
wherein a significant increase in the amount of the marker in the subject sample relative to the normal amount of the marker in the non-multiple myeloma control sample is an indication that the subject is afflicted with multiple myeloma.
3. A method of assessing whether a subject is afflicted with multiple myeloma, the method comprising:
a) determining the amount of a marker in a subject sample comprising plasma cells, wherein the marker is DHX36; and
b) determining a normal amount of the marker in a non-multiple myeloma control sample comprising plasma cells; and
c) comparing the amount of the marker in the subject sample and the normal amount of the marker in the non-multiple myeloma control sample,
wherein a significant increase in the amount of the marker in the subject sample relative to the normal amount of the marker in the non-multiple myeloma control sample is an indication that the subject is afflicted with multiple myeloma.
4. The method of claim 1 , 2 , or 3 , wherein the amount of the marker is determined by determining the level of expression of the marker.
5. The method of claim 1 , 2 , or 3 , wherein the amount of the marker is determined by determining copy number of the marker.
6. The method of claim 1 , 2 , or 3 , wherein the subject and control sample is selected from the group consisting of tissue, whole blood, serum, plasma, buccal scrape, saliva, cerebrospinal fluid, urine, stool, and bone marrow.
7. The method of claim 5 , wherein the copy number is assessed by comparative genomic hybridization (CGH).
8. The method of claim 7 , wherein said CGH is performed on an array.
9. The method of claim 1 , 2 , or 3 , wherein the level of expression of the marker in the subject or control sample is assessed by detecting the presence in the subject or control sample of a protein corresponding to the marker.
10. The method of claim 9 , wherein the presence of the protein is detected using a reagent which specifically binds with the protein.
11. The method of claim 10 , wherein the reagent is selected from the group consisting of an antibody, an antibody derivative, and an antibody fragment.
12. The method of claim 1 , 2 , or 3 , wherein the level of expression of the marker in the sample is assessed by detecting the presence in the sample of a transcribed polynucleotide or portion thereof, wherein the transcribed polynucleotide comprises the marker.
13. The method of claim 12 , wherein the transcribed polynucleotide is an mRNA.
14. The method of claim 12 , wherein the transcribed polynucleotide is a cDNA.
15. The method of claim 12 , wherein the step of detecting further comprises amplifying the transcribed polynucleotide.
16. The method of claim 1 , 2 , or 3 , wherein the level of expression of the marker in the subject or control sample is assessed by detecting the presence in the subject or control sample of a transcribed polynucleotide which anneals with the marker or anneals with a portion of a polynucleotide wherein the polynucleotide comprises the marker, under stringent hybridization conditions.